Home Featured Page 294

Featured

Latest

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction...

Psilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using...

Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and...

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics...

COMPASS Pathways granted two US patents

Mydecine Innovations Group Announces Migration to NEO Exchange

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

PTSF52 – Start Low, Go Slow

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction...

Psilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using...

Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and...

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics...

COMPASS Pathways granted two US patents

Mydecine Innovations Group Announces Migration to NEO Exchange

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY